Table 3.
Associations between transgender gender identity and mortality after cancer diagnosis by cancer site among patients in the National Cancer Database 2003-2013
| Cancer site and gender identity | No. of deaths | HR (95% CI)a |
|---|---|---|
| Anus, anal canal, and anorectum | ||
| Cisgender | 16 193 | 1.00 (Referent) |
| Transgender | <10b | 1.01 (0.52 to 1.94) |
| Breast | ||
| Cisgender | 358 042 | 1.00 (Referent) |
| Transgender | <10b | 1.23 (0.59 to 2.58) |
| Kidney and renal pelvis | ||
| Cisgender | 127 260 | 1.00 (Referent) |
| Transgender | <10b | 1.72 (0.82 to 3.61) |
| Liver and intrahepatic bile duct | ||
| Cisgender | 111 818 | 1.00 (Referent) |
| Transgender | 19 | 1.06 (0.68 to 1.67) |
| Lung and bronchus | ||
| Cisgender | 1 047 162 | 1.00 (Referent) |
| Transgender | 46 | 1.13 (0.85 to 1.51) |
| Melanoma of the skin | ||
| Cisgender | 78 729 | 1.00 (Referent) |
| Transgender | <10b | 1.06 (0.51 to 2.22) |
| Non-Hodgkin lymphoma | ||
| Cisgender | 165 989 | 1.00 (Referent) |
| Transgender | 20 | 2.34 (1.51 to 3.63) |
| Pancreas | ||
| Cisgender | 212 072 | 1.00 (Referent) |
| Transgender | 12 | 1.37 (0.78 to 2.42) |
| Prostate | ||
| Cisgender | 261 123 | 1.00 (Referent) |
| Transgender | 11 | 1.91 (1.06 to 3.45) |
| Rectum | ||
| Cisgender | 128 998 | 1.00 (Referent) |
| Transgender | 12 | 1.32 (0.75 to 2.33) |
| Urinary bladder | ||
| Cisgender | 118 948 | 1.00 (Referent) |
| Transgender | <10b | 2.86 (1.36 to 6.00) |
aAdjusted for age at diagnosis, (18-44, 45-54, 55-64, or 65 years and older), year of diagnosis (2003-2007, 2008-2011, or 2012-2013), race and ethnicity (non-Hispanic White, Black, Hispanic, or other), AJCC stage (0-II, III/IV, or unknown), and treatment (yes or no). AJCC = American Joint Committee on Cancer; CI = confidence interval; HR = hazard ratio.
bCells with more than 0 but fewer than 10 individuals are suppressed.